What is TRIKAFTA and who is it for?

TRIKAFTA is a new medicine approved by the FDA for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation. It is a combination therapy including elexacaftor, tezacaftor, and ivacaftor.

How will TRIKAFTA's approval impact Vertex's financial outlook?

The approval of TRIKAFTA led Vertex to increase its full-year 2019 guidance for CF net product revenues to a range of $3.70 billion to $3.75 billion, up from the previous forecast of $3.60 billion to $3.70 billion. This indicates strong market reception and revenue potential for the new drug.

What is the annual cost of TRIKAFTA in the U.S.?

Vertex has set the wholesale acquisition cost for TRIKAFTA in the United States at $311,503 on an annual basis.

What are the risks associated with Vertex's forward-looking statements?

Vertex's forward-looking statements, including revenue guidance, are subject to risks and uncertainties. These could cause actual results to differ materially from expectations. Factors include the possibility that underlying assumptions may not be realized and other risks detailed in Vertex's SEC filings.

VRTX 8-K: Regulation FD

Summary

Vertex Pharmaceuticals announced a significant development on October 21, 2019, with the U.S. Food and Drug Administration (FDA) approval of TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor). This new treatment is indicated for cystic fibrosis (CF) patients aged 12 and older who possess at least one F508del mutation, representing a broad segment of the CF population. The approval of TRIKAFTA, a combination therapy, is expected to be a major driver of future revenue and further solidifies Vertex's market leadership in CF treatment.

Key Highlights

1FDA approval of TRIKAFTA™ for cystic fibrosis patients aged 12+ with at least one F508del mutation.
2TRIKAFTA is a novel combination therapy offering expanded treatment options.
3Established U.S. wholesale acquisition cost for TRIKAFTA at $311,503 annually.
4Increased full-year 2019 CF net product revenue guidance to $3.70 billion - $3.75 billion.
5The previous 2019 CF net product revenue guidance was $3.60 billion - $3.70 billion, indicating an upward revision.
6The early approval of TRIKAFTA is a key factor in the increased revenue guidance.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Regulation FD Disclosure (Oct 21, 2019)

Summary

Key Highlights

Frequently Asked Questions